"The primary end point was met, showing a statistically significant rPFS benefit with the combination of capivasertib and abiraterone," said Karim Fizazi, MD, PhD. Adding the oral AKT inhibitor ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...
Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes. Testosterone therapy was not associated with an ...
An expert discusses how the greatest unmet need in minimally invasive benign prostatic hyperplasia (BPH) treatments is achieving durability and retreatment rates that match those of surgical options ...
An expert discusses how the proposed Centers for Medicare & Medicaid Services (CMS) rule represents an unusual circumstance that benefits smaller private practices by reducing work relative value ...
Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist. In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, ...
Krambeck highlights that FANS combine enhanced maneuverability and effective fragment evacuation, leading to higher stone clearance rates and improved procedural outcomes in endourology. In this video ...
Modern visualization tools have reduced fluoroscopy use, enhancing direct visualization in kidney stone procedures. Single-use ureteroscopes offer superior deflection and image quality, though cost ...
In this episode of First Assist: GU Oncology Unpacked, host Taylor Goodstein, MD, speaks with Tullika Garg, MD, MPH, FACS, a urologic oncologist at Geisinger Medical Center in Danville, Pennsylvania, ...
VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...
Apolo highlighted the positive topline results from the phase 3 EV-303 trial (NCT03924895) evaluating EV plus pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer. In ...
FGFR inhibitors are vital in bladder cancer treatment but face challenges due to significant toxicities, limiting long-term use. Dabogratinib selectively targets FGFR3, aiming to reduce toxicities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback